Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Clinical pharmacokinetics - 1 Jan 2012

Verstuyft Céline, Delavenne Xavier, Rousseau Alexandra, Robert Annie, Tod Michel, Diquet Bertrand, Lebot Martine, Jaillon Patrice, Becquemont Laurent

Abstract excerpt

BACKGROUND AND OBJECTIVE: Vitamin K epoxide reductase complex, subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) polymorphisms are taken into account when predicting a safe oral dose of coumarin anticoagulant therapy, but little is known about the effects of genetic predictors on the response to fluindione and acenocoumarol. The aims of this study were to characterize the relationship between fluindione and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP1A2

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 22149257
DOI: 10.2165/11595560-000000000-00000

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.PMID 22149257Read ↗

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.Semantic proximity Read ↗

Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.Semantic proximity Read ↗

An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.Semantic proximity Read ↗

A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various CYP2C9 Genotypes under Different Cotreatments.Semantic proximity Read ↗

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.Semantic proximity Read ↗

Creating a genotype-based dosing algorithm for acenocoumarol steady dose.Semantic proximity Read ↗

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.Semantic proximity Read ↗

Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.Semantic proximity Read ↗

Phenotypic models of drug-drug-gene interactions mediated by cytochrome drug-metabolizing enzymesSemantic proximity Read ↗

Phenotypic Models of Drug-Drug-Gene Interactions Mediated by Cytochrome Drug-Metabolizing Enzymes.Semantic proximity Read ↗

Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.Semantic proximity Read ↗

Time-to-event modeling for achieving a stable warfarin dose using genetic and non-genetic covariates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.